- Home
- MYN vs HUMA Comparison
MYN vs HUMA Comparison
Compare MYN & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- HUMA
- Stock Information
- Founded
- MYN 1992
- HUMA 2004
- Country
- MYN United States
- HUMA United States
- Employees
- MYN N/A
- HUMA N/A
- Industry
- MYN Finance Companies
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- HUMA Health Care
- Exchange
- MYN Nasdaq
- HUMA Nasdaq
- Market Cap
- MYN 358.2M
- HUMA 250.2M
- IPO Year
- MYN N/A
- HUMA N/A
- Fundamental
- Price
- MYN $9.31
- HUMA $1.51
- Analyst Decision
- MYN
- HUMA Strong Buy
- Analyst Count
- MYN 0
- HUMA 8
- Target Price
- MYN N/A
- HUMA $10.88
- AVG Volume (30 Days)
- MYN 86.0K
- HUMA 5.9M
- Earning Date
- MYN 01-01-0001
- HUMA 08-11-2025
- Dividend Yield
- MYN 4.12%
- HUMA N/A
- EPS Growth
- MYN N/A
- HUMA N/A
- EPS
- MYN N/A
- HUMA N/A
- Revenue
- MYN N/A
- HUMA $818,000.00
- Revenue This Year
- MYN N/A
- HUMA N/A
- Revenue Next Year
- MYN N/A
- HUMA $949.92
- P/E Ratio
- MYN N/A
- HUMA N/A
- Revenue Growth
- MYN N/A
- HUMA N/A
- 52 Week Low
- MYN $8.47
- HUMA $1.15
- 52 Week High
- MYN $10.62
- HUMA $6.77
- Technical
- Relative Strength Index (RSI)
- MYN 48.18
- HUMA 36.87
- Support Level
- MYN $9.20
- HUMA $1.43
- Resistance Level
- MYN $9.33
- HUMA $1.67
- Average True Range (ATR)
- MYN 0.07
- HUMA 0.15
- MACD
- MYN -0.01
- HUMA -0.01
- Stochastic Oscillator
- MYN 50.00
- HUMA 23.32
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.